Eli Lilly (NYSE: LLY), a pharmaceutical manufacturer, has announced a significant investment of approximately $5 billion to construct a new factory near Richmond, Virginia, focused on producing antibody-drug conjugates. This venture marks a notable expansion for the company, potentially impacting its investors positively by enhancing its production capabilities for targeted medications.
